Rigosertib
| Title | Journal |
|---|---|
| ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex. | Translational research : the journal of laboratory and clinical medicine 20160901 |
| A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20150901 |
| Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. | Oncotarget 20150821 |
| Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. | Hematological oncology 20150601 |
| Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. | Cancer science 20150301 |
| In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide. | Molecular pharmacology 20150101 |
| Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na. | Molecular cancer therapeutics 20140501 |
| Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities. | Journal of medicinal chemistry 20140327 |
| Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20140315 |
| Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. | Scientific reports 20140101 |
| The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. | Molecular cancer therapeutics 20131001 |
| Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. | Leukemia 20130901 |
| Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. | British journal of haematology 20130801 |
| A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay. | PloS one 20130101 |
| Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001. | Laboratory investigation; a journal of technical methods and pathology 20121001 |
| Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. | Leukemia research 20120801 |
| Targeting cyclin D1 for high risk myelodysplastic syndromes. | Leukemia research 20120801 |
| Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120401 |
| ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120401 |
| Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. | Leukemia research 20120101 |
| Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. | Journal of pharmaceutical and biomedical analysis 20111215 |
| Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. | Seminars in oncology 20111001 |
| Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. | Journal of medicinal chemistry 20110922 |
| Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. | Cancer research 20110715 |
| Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors. | Bioorganic & medicinal chemistry letters 20110515 |
| Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials. | Drug metabolism and disposition: the biological fate of chemicals 20100901 |
| Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. | Cancer chemotherapy and pharmacology 20091201 |
| Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. | The oncologist 20090601 |
| Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. | Oncogene 20090326 |
| Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. | Oncogene 20090129 |
| Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201 |
| Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901 |
| BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. | Current biology : CB 20070220 |
| Probing cell-division phenotype space and Polo-like kinase function using small molecules. | Nature chemical biology 20061101 |
| Polo-like kinase (Plk) 1 as a target for prostate cancer management. | IUBMB life 20051001 |